Follow-On Grudge Match: The Round One Scorecard In Waxman vs. Eshoo
Executive Summary
Two versions of biosimilars legislation are now before the House, and the question is how much, if any, compromise will be needed to get a measure approved on that side of Capitol Hill
You may also be interested in...
Follow-On Biologics Legislation Faces Tough Road Ahead; Momentum Stalled
Prospects for enactment of follow-on biologics legislation appear limited in the near term, according to Capitol Hill players in the debate
Follow-On Biologics Legislation Faces Tough Road Ahead; Momentum Stalled
Prospects for enactment of follow-on biologics legislation appear limited in the near term, according to Capitol Hill players in the debate
Follow-On Biologics Bill’s Prospects Are Uncertain, Waxman Staffer Says
Busy House committee schedule and “fractured” Senate will make reaching consensus a challenge, Ann Witt says, but potential inclusion of FOBs into health reform bill is “wildcard.”